Rize Oncology Management

Management criteria checks 2/4

Rize Oncology's CEO is Daren Graham, appointed in Jul 2025, has a tenure of less than a year. directly owns 11.66% of the company’s shares, worth $1.41M. The average tenure of the management team and the board of directors is 4.1 years and 4.6 years respectively.

Key information

Daren Graham

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	11.7%
Management average tenure	4.1yrs
Board average tenure	4.6yrs

Recent management updates

Recent updates

CEO

Daren Graham (53 yo)

less than a year

Tenure

US$49,803

Compensation

Mr. Daren N. Graham, J.D., Esq., serves as Chairman at GeneTether Inc. He served as Interim Chief Financial Officer at Tryp Therapeutics Inc. since February 3, 2022 until February 18, 2022. He is Chairman...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Daren Graham	Interim CEO & Executive Chairman	less than a year	US$49.80k	11.66% $ 1.4m
William Garner	Co-Founder & Executive Director	7.6yrs	no data	63.97% $ 7.8m
R. Sargent	Co-Founder & Chief Scientific Officer	7.6yrs	no data	no data
Jim O'Neill	Chief Financial Officer	less than a year	no data	no data

4.1yrs

Average Tenure

59yo

Average Age

Experienced Management: RZON.F's management team is considered experienced (4.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Daren Graham	Interim CEO & Executive Chairman	4.6yrs	US$49.80k	11.66% $ 1.4m
William Garner	Co-Founder & Executive Director	7.3yrs	no data	63.97% $ 7.8m
P. Jull	Independent Director	3.8yrs	no data	0.20% $ 23.8k
Andre Pereira Figueiredo	Independent Director	4.6yrs	no data	5.08% $ 615.8k

4.6yrs

Average Tenure

56yo

Average Age

Experienced Board: RZON.F's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/08/20 07:10
End of Day Share Price	2025/05/23 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rize Oncology Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.